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Chapter 8
Summary and general discussion
Antipsychotic drugs are not only effective for psychosis, but also for Tourette's
syndrome. Their use is limited by their extrapyramidal side-effects (EPS). An
atypical antipsychotic can be defined as a compound that has a significant anti-
psychotic action on positive symptoms but with no or few EPS (Meltzer 2000).
This definition is often expanded to include efficacy in treatment-resistant schi-
zophrenia, amelioration of negative- and cognitive symptoms, and the lack of
sustained prolactin elevation.
The main objectives of the present thesis, clivided in a preclinical and a clinical
part, were to stucly the atypical antipsychotic risperidone with respect to 1) its
mechanism of atypical arction, ancl 2) its potentials in Tourette's svndrome.
The major f indings of the present thesis are as follows:
PART I (chapter 2-4) investigatecl sotne aspects of the rnechanism of the
"atypical" action of the atypical antipsychotic risperidone in the basal ganglia,
using in rrioo extracellular single cell recordinp;s. ln our electrophysiological stu-
dies of the fir ing pattern of midbrain dopamine neurons in vivo, rispericlone
displayed a so-callecl mesolimbic-selective profile, corresponding to an atypical
action profile. Secondly, in similar studies of GABA-ergic neurons in the sub-
stantia nigra reticulata (SNr), we found that the neuronal activity of the SNr
readily discriminates between the classical neuroleptic haloperidol and the aty-
pical antipsychotics risperidone and clozapine. Thus we propose that these
experimental models possess significant predictive validity in the identif ication
of drugs with an atypical antipsychotic profile.
PART II (chapters 5-7) aimed at cletermining risperidone's therapeutic
potential in Tourette's syndrome, a disorder thought to be strongly related to a
dopamine dysfunction within the basal ganglia. The conclusion to be drawn
from the three clinical studies described here is that atypical antiosychotics,
such as risperidone, may possess significant therapeutic efficacy in the treat-
ment of Tourette's svndrome.
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Risperidonc dffircntialltl affccts nidbrain dopatrinc nturotrs
Chapter 2 describes the acute effects of risperidone and halopericlol on firing
pattern of rnesocorticolimbic dopamine lleurons in the ventral tegmental area
(VTA) ancl the nigrostriatal dopamine rleurons originating in the substantia
nigrar compacta (SNc), dopamir-re pathways generally associatecl with the anti-
psycl-rotic action ancl EPS liabil i ty of antipsvchotic clrugs, respectively.
Using extracellular single cell recorclings in virro, we founcl that risperido-
ne increase-c'l the fir ing rate arncl the burst f ir ing of VTA dopamine neurons in a
close c'lepenclent manner. Yet, rispericlorre failccl to significantly affect the firing
pattern of SNc-doparnine neurons. In cclntrast, haloperic' lol increasecl the fir ing
ratc. of both VTA and SNc neurons, whereas burst f ir ing increasecl only at the
highest close'teste'cl, arrcl dicl so in both populations. These results riernonstrate
tl 'rat rispericlone, but not halopericlol, preferentitrl lv activates rncsocorticolirnbic
clopamine neurons origirrating in the VTA, with a rclative sparing of the stria-
tal projectirrg SN clopamine neurons. This lower propensity to activatc the
nigrostriatal dopanrine systern is compatible n,ith comparative less impairment
of clopamine function in motor corltrol circuitry, implicating a low propensity
for EPS, i.c. an atypical mocle of action.
Thc activation of burst f ir ing in VTA clopamine neurons inciucecl by rispe-
riclone mav inrl icate an irnprovement of the antipsychotic efficacy of this clrug
in comparison to classical arrtipsychotics. Thus, an increase in burst f ir ing of
l imbocorticarl projecting neurons, i.e. a more phasic than tonic activity, implies
an enharrcecl signal-to-noise ratio of dopanrirre signirl ing in these neurons. This
Inay consequently lead to a morc adequate responsiveness to rrovel stimuli,
w,hich may be of importance cluring behavioral adt-rptation to new environ-
rnents ancl during learning (Schultz et al., 1993, Schultz et al.,79L)7; Svcrrsson,
2000). Burst activation of cortical VTA clop;rmine ueurons has prcvictusly been
prol-rosed to represent a novel rnechanism by which potent 5-HT2^ receptor
autagonists ame'l iorate prefrorrtal cortical clopamine function, ar dopamine plo-
jection frequently associated with ncgative ancl cognitive symptomatology in
schizopl-rrenia (sce Svenssc'rn et al., 1995; Weinbcrger, 1987).
The prcsent stucly supports previous eviclence, n'hich inc'l icates that 5-HT2n
antagonism, when addec-l to relativclv nroclerate clopamine D"-antagonism, pre-
fcrgrtiallv activates mesocorticolimbic doparnine proje.ctions as well ;rs burst
fir ing in VTA neurons (Anclcrson et al., 1995; Svensson ct al., 1995). The rnecha-
nistn of action for rispericlclne presumably inr,,olvcs interference r,r ' i th a numbe.r
of ne'urotrtrrrsnritter systerns. Thcse ncurotransmitters, apart from clopamitre
receptor antagorrism, c..q. 5-HT antl NA, mav act upon remote systems, such as
cortical structurcs witlr neuronal input to the miclbrtrin rlopamine nc-urons. In
aclclition, se.rotorrergic antl nor.rclrenergic irrputs to the VTA h.tve botl.r bcc.n
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demonstratecl to modulate the firing pattern of VTA dopamine neurons (Ugedo
etaI.,7989; Crenhoff and Svensson, 1988). Renewed studies on risperidone with
pretreatment with a 5-HT agonist and a NA-agonist appear warranted to deter-
mine the relative contributiorrs of e.g. 5-HTrA-, cx1-, or o,2- receptor antagonism in
the specific responses elicitecl by risperidone in the SNc and VTA.
There are some caveats to this study. The study is limited to only acute
administration of drugs, while long-term treatment with antipsychotics has
also been reportecl to alter the firing pattern of midbrain dopamine neurons. In
this respect, it should also be noticed that acute administration of high doses of
risperidone in this model did not further alter the response profile, although it
is known that risperidone in corresponding doses in psychiatric patients often
can lead to development of EPS (see introduction). Comparisons with chronic
treatment with these antipsvchotics appear warranted in orcler to more faith-
fuliy rnodel the clinical situation, in which both antipsycirotic action and most
of the motor side effects are observed only after several rn'eeks of treatment.
Nevertheless, this apparently lower face validity of this type of study does not
necessarily alter the empirically established predictive validity of this type of
experiment (Crace et a1.,7997)
In the present study depolarization-block n'as not subject of stucly.
According to the studies of Crace et al. (cf. Grace et a1.,1997) the depolarization
block theory of antipsychotic action proposes that inactivation of miclbrain dopa-
mine neurons is a crucial ancl delayed event in the induction of the therapeutic
effect of neuroleptics. However; this phenomenon apparentlv cannot be repro-
duced in the awake, paralyzecl preparation ancl mav well be an artifact inducec-l
by use of chloral hydrate anesthesia (Mereu et a1.,7995; Melis et al., 1998). ln the
present stucly, some cells dicl show an acute depolarization block during the close
response trial, resulting in a silencing of the dopamine neuron, which returned to
a firing mode after apomorphine administration (data not shown). These results
were excludecl from further analvsis. Regardless of the putative influence of chlo-
ral hyclrate anesthesia on the responsiveness of the firing patterns of n-riclbrzrin
dopamine neurons to antipsychotic drugs, this experimental paradigm remains a
robust and reliable means of differentiating antipsychotic drugs with classical
from atypical profiles, and has thus empirically been shown to possess a high
predictive valiclity (Crace et aI.,7997). Novel techniques e.g. electrophysiology irr
awake anirnals hold promise by errtirely circumventing the shortcomings of use
of anesthesia in the near future. Nevertheless the theory of depolarization block
appears incompatible with adequate physiological functionirrg of the individual
since widespread depolarization block of dopamine neurons in vivo would not
allow sufficient dopamine response dynamics for the individual to respond in a
timely manner to various stirnuli and situations.
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As for Tourette's syndrome, these findings can be interpreted as follows. The
mesolimbic dopamine system projects unto the ventro-meclial striatum, a region
ir-rtimately coupled to limbocortical circuitry. [n rodents strong mesolimbic dopa-
mine output is correlated with rewarding and addictive stimuli, with behavioral
activation, i.r. an increasetl locomotor activity and with stereotypy (Fibiger et a1.,
7992; Westerink et al., 7997; Gessa et al., 7998). All these effects can readily be
blocked by both classical and atypical antipsychotics. It has been hypothesized
that the ventral-medial striatum is involvecl in the clinical characteristics of
Tourette's syndrome (see Brito, 1997). Tentatively, risperidone's preferential effect
orr the mesolimbic system may implicate an improved efficacy for Tourette's
symptoms. Concomitantly, the relative sparing of the nigrostriatal DA system is
compatible lr,ith a low incidence of EPS. Following this theory of mesolimbic
selectivity other atypical antipsychotics might also be expected to be beneficial in
Tourette's syndrome. Indeed, recent findings with olanzapine and ziprasidone,
both atypical antipsychotics with a high sF{T"/D2affinitv ratio were shown to be
effective trgents in Tourette's synclrome (see below). However, clozapine lvas not
found to be effective in a small study in hyperkinetic disorders (Caine et al.,
1979). Conceivably, this may be due to the fact that clozapine has a very low affi-
nity for the D2 receptor. The significant therapeutic responses of tics to substitu-
ted benzamides, tiapride, sulpiricle and remoxipride, Ient further support for a
role of the rnesolimbic selectivity (Eggers et al., 1988; Robertson et a1., 1991;
Buitelaar et al., 1995). These atypical antipsychotics also have been proposecl to
possess higli affinity for the ventromedial striatum. Yet, the benzamides are not
"multireceptor" antagonists like clozapine but relatively selective dopamine
Dz/Dz antagonists. This suggests a different rnecharrism underlyirrg their atvpi-
cal action, terrtativelv based on e.g. their much higher affinity for the Dj-receptors,
which are found in high concentrations in the target areas of the mesolirnbic
dopamine system (see Sokoloff et al., 1992;Den Boer and Korf,2000).
Ttre incretrsed burst firing of the VTA do1-s11in" nerlrons, as seen with ris-
preridone rnay indicate an improved capacity of dopamine cells to responcl ade-
quately to salient stinluli (Svensson et al., 1995). In this respect, the brarin's
disturbed gating function as proposed by Carlsson (1988) to underlie schi-
zophrenia, may also serve as a putative model to unclerstand the rreurobiology
of Tourette's syndrome. Such a gating function may very well be not restricted
to a "thalamic fllter" , but can also be located in several other parts of the brain,
c.g. t lre prefrontal cortex or the nucleus accumbens (Carlsson et al., 2000, Grace,
2000). Tourette's synclrome is characterizecl by a heightened sensitivity to inter-
nal somatosensory as well as external environmental cues (See Anderson et a1.,
1999), suggesting that the brain is in a state of "hypersalience". Clearly the
tlopamine system htrs a strong rnoduiating infiuence on this salience svstem.
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Dynamic variations of clopamine cells, as seen with increased burst firing, may
be an irnportant mechanism for the brain to aclapt to ne.w situations (Shultz et
aL.,1993). Tentatively, in Tourette's syndrome an improvement of the dynamic
respollse range of dopamine activitv in re'sponse to enrzironmental stimuli mav
help to alleviate situationally inappropriate or irrelevant behavioral output, e.g.
tics (cf. Carlsson et al., 2000; Crace, 2000; Svensson, 2000).
I{esearch to elucidate the mechanisms of action of atypical antipsychotics
in tic suppression is sparse anr'1 therefore arrv hvpothesis is sti l l  rather specula-
tive. Obviously, there may very well be several pathcrprhysiological differences
between sclrizopluenia trr-rd Tourette's svnclrome that nray explain clifferenccs
in therapeutic efficacy in these two conditions. Nevertheless, irnproving
dopaminergic functions in the mesolimbocortical systerrr mav be hvpothesized
as means for at1'pical antipsychotics to exert lrofh antipsl,chotic and tic-sup-
pressive action. On balance these firrc-l ings ugp;est hat there rnay theoretically
be several pharmacological means to aclrieve an "atvpical" antipsychotics pro-
fi le not only in schizoplrrenia, but irr t ic-disorders as well.
Effact o.f rispcriLlLtnc, loztrltine nrrd ltolttpcridttl on ncttronttl nctititll ty' fhc SNr
The nrodel described above reliably detects clifferenti;rl effects of antipsycl-rotics
on the mesolimbic-mesocortical vs. the nigrostriatal rlopaminergic syste.m at
the cell body level. Howeve4 these two cloparninergic systems are part of tl-re
basal ganglia, in which their role is clearlv moclulatory in character (review:
DeLong, 1990). Projections of these two clopaminergic systems arc. not cclnfinecl
to l imbic vs. striatal postsynaptic structures (Nauta anrl Domc.sick, 1984; Gerfen
et al., 1985). Therefore, insight in the conseLluences of specific changes in
dopaminergic activit l. for postsynaptic stluctures should contribute to uncler-
standing how tl 'rerapeutic ar.rd sicle effects of neuroleptics are mecliatecl.
The output neurons of the basal ganglia may providc. goocl alternative
structures to investig.rte. The SNr, togetl-rer witlr the CPi, is corrsiderecl to repre-
sent a rnajor part of these output nuclei. The SNr neurons receive cortically ori-
girrarting arfferents via the dorsolateral striatum ancl they exert an irrhibitory acti-
on on thalirmo-cortical target areas. Thus, the SNr is located in a postsynaptic
targct areer of the striartum and may thercfore play a pivotal role in the routing
of inforrnation from thc. cortex through the basal gar-rglia unto the thalamus and
relzrted cortical areas.
We therefore hypothesized, in chapter 3, that the SNr may prove useful as
an experimentarl basis for urrderst.rnding some trspects of the arrtipsychotic acti-
on-mechanisms. Using extracellular recordings, we compared risperidone, clo-
zaprine and halopericlol with reslrect to their effects on the neuronal activity of
GABA-ergic neurons in the SNr. Tl-ris stucly dernonstrates that risperidone and
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clozapine inhibits SNr neurons, whereas haloperidol had little effect or slightly
enhanced the neuronal activity. Thus, our data suggested a correlation between
the activity level of the SNr and the atypical character of antipsychotics.
Tlrc role of SHT2/D2 antagonism in the atypicol actiott on SNr actiaitrl
Several authors have postulated that concurrent 5-HT2- and D2-antagonism is
essential for the atypical character of a number of these new antipsychotics;
more specifically, a high S-HTrn/D2 occupancy ratio (Meltzer, 1989, Deutch et
a1.,7997). We therefore evaluated the role of serotonin (5-HT) in this differenti-
al effect of typical and atypical antipsychotics on the SNr activity. Indeed, pre-
treatment with the non-specific S-HT agonist quipazine partially blocked the
characteristic inhibitory effect of risperidone, thus suggesting a serotonergic
involvement in the moclulation of the SNr neuronal activity.
In chapter 4 the contribution of the S-HT2A-receptor antagonism was fur-
ther investigated. Our hypothesis was that a combination of LY 53857, a potent
and selective S-HT2a72s-receptor antagonist and raclopride, a selective D2 -
receptor antagonist would induce a similar effect on SNr activity as observed
with the atypical antipsychotics. lt was found that such a combined 5-HT2/D,
receptor blockade could mimic the action profi le of risperidone ancl clozapine
on the SNr neurons. lnterestingly, the closages of the D2 antagonist pretreat-
ment turned out to be essential for the atypical-like effect. Thus, modification
of the neuronal response by the 5HT2n7g-receptor antagonist was accomplished
by pretreatment with low but not high doses of the D2-receptor antagonist
raclopride. This observation corresponds with a number of pre-clinical data
(see introduction). It also is in accordance with the clinical notion that the aty-
pical profile of most atypical antipsychotics is lost wherr the D2-receptor bloc-
kade exceeds a certain threshold, i.e. > 75-80'/o D2 receptor occupancy (Farcle et
a1.,7992; Kapur et al., 1996, Kapur et al. 1999).
Tlrc neuronnl actirtitll of tlrc SNr ns experirnental ntodel to predict nn ahpical nction profle
Using the same experimental setup, Timmerman and co-workers found that the
acute administration of the atypical antipsychotic olanzapine also inhibits the
SNr activity (Timmerman et a1., 1999). This finding supports the SNr-neuronal
activity model as a screening test for atypical antipsychotics.
For a paracligm to have predictive validity, it should first be determined
whether the observed effect predicts a therapeutic action or unwanted side
effects, or both. In general, similarities between new drugs and haloperidol
may select for drugs with an antipsychotic action, but also with the propensity
to induce EPS. Differences between a new drug and haloperidol may hint to an
atypical profi le. Moreover, similarit ies with clozapine may give clues to an aty-
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pical mechanism, e..q. ls6, propensity for EPS, alleviation of negative syrnptotns
or improvement of cognitive functioning. Hor.r,ever, it should be kept in mind
that efficacy on these latter symptom clusters are most reliably studied in spe-
cif ic behavioral rnodels. Nevertlreless, since adrninistration of haloperidol sho-
wed an effect opposite to clozapine and risperidone, the response of the SNr
neurons may apparently not be related to an antipsychotic effect, as the three
compounds do not essentially differ in this respect. Therefore, the clinical cor-
relates of the SNr neuronal activity could theoretically point to certain specific
atypical aspects of these compounds (see trlso Midelleton and Strick, 2000).
A general criterion for a screening model states that clrugs of clifferent che-
mical structures shc.ruld t're active in this moclel (see Ellenbroek,7993; Ellenbroek
and Cools, 2000). Using the SNr neuronal activity as a screening model for atv-
picality, two dibenzazepines (olanzapine and clozapine) ancl one bensizoxazol-
clerivative (risperidone) tested "positirre", whereas one butyrophenone (halope-
ridol) tested "negative". The 5-HT receptor agonist quipazine was able to anta-
gonize the effect of risperidone. This cornpound hzrs not been used as ir clinicarl
probe. Notabll ' , combinecl 5-HT2/D, antagonism also tested "positive", i.r. had
an inhibitory effect on SNr neuronal firing. The D2-receptor antagonist raclopri-
de te.stecl "negative", i.c. its response was similar to haloperirlol. Raclopride h.rs
underp;one clinical trials, but it was not marketed since it did not possess an aty-
pical antipsychotic profile. The 5-HT2,1/2c receprtor antagonist LY53878 tested
"ne5;ative" in the low dose range, but gave an inhibitory "atypical-like" respon-
se irr the high dose range. Wl-rether this inhibitory effect of LY 53857 woulcl rela-
te to an atypical action profi le for 5-HT,-receptor antagonists is an interesting
issue that awaits clinical confirmation. The novel and highly selective 5-HT2A-
receptor antagonist M 100,907 is undergoing advanced clinic;rl testing ;rnd the
tentative efficacy of this compound may shed further light on this issue.
In the present experiments, the SNr activitv was evzrluatecl in an acute
dose-response curve moclel. l-he characteristic inhibitorv effects lr,ere achievecl
already at low doses. If the inhibition of SNr activity cloes incleerl relate to the
moclulation of rnotor sicle effects, it appears preclicted that tl-re "at;'pical-like"'
response of rispericlone may change into a "typicall ike" response for the hig-
her dose-range, since the atypical profi le of risperidorre does not holcl for high
closes in schizophrenic patients. However, the acute experiments with risperi-
done did not show a dose-dependent correltrtion between the doses of risperi-
done and the atypical-l ike response. In fact, the inhibitory effects of risperirlo-
ne on the SNr seemed to plateau already in the lower close range anr'l to stay
unchanged afterward. In contrast, in the pretreatment experiments, there lt'as a
differential effect between low ancl high doses of D2 blockade. Thus, for the




was founcl only with low, but not high closes of D2 receptor antagonist.
Another important aspect of animal models for antipsychotic treatment con-
cerns the delayed onset of the antipsychotic effect in clinical practice. The issue of
chronic treartment was not t'rcltlressed in the current work. In the publicatiorr try
Timrnerman et al. (1999) the effect of chronic h€ahnent r,r'as studied for olanz.rpi-
ne and clozapine. It was found that after chronic treatment with 1 mg/kg per clay
for three weeks, challenge with olanzapine resulted in an inhibition of the SNr
activity, sirnilar to the one seen with acute treatment of olanzapine, rispericlone
arnd clozapine. In addition, the long-term tre;rtment experimerrts in the studv l-ry
Timmermarn trncl co-workers evaluated the effect of two different dosage reginrens
of the atvpical antipsychotic olanzapine (Tirnmerman et aI., 1999).In that sttrdy, a
low dosage regimen of olarnzapine vieldecl a similar response for both acute and
chronic treatment (see above). However, following chronic treatment with a rela-
tively high dose of olanzapine (smg/kg/day), the challenge with cumulative
dose-s of olanz;.rpine dicl not significantly affect the neuronal trctivity of the SNr;
comparable with long-tern'r administration of haloperic{c'rl. Thus, the atypiczrl pro-
file witl-rin this rnoclel wtrs lost in a high c-lose regimen of olanzapine. Tretrtment
with comparable high doses of olanzapine has yielded catalepsy in rats in one
study, whe.reas in other ele'ctrophysiological studies mesolirnbic selectivity was
preserved at e-r,en higher doses (Skarsfek-lt, 1995; Stockton anr'l Rasmussen, 1996).
Interestingly, clozapine vielcled an atyprical-like reaction after clrronic higl-r close
treatment (Timmerman et al, 1999). We did not test chror-ric treatment with rispe-
riclone in these studies. Further experiments may reveal if chronic treatment with
high closages of risperidone woulcl give similar results as olanzapine.
Finallr', a general point of discussion concerns the effect of general anesthe-
sia on the fir ing pattern in the SNr preparatiorrs. In awake arrirnals slow oscil la-
tions arre seen that prcsumably are depenclent on the ongoing activity ir-r arfferent
structures, whereas there is a remarkable lack of significant oscillatory activity
under chloral hydrate anesthesia (cf. Ruskin et al., 1999). Moreovet in freely
moving rats, movement-relarted elevatiorrs of firing in SNr-neurons were seen as
the major r€.sponse, althotrgh inhibitjons wc-re also observerl (Culley et al., 1999).
Taken together, the present studies and the report by Timmerrrrtrn t-.t al.,
(1999), support predictive validity of this experimental paradigm within the
SNr as a novel technique to assess the putative atypical arrtipsychotic effects of
erpcr imenta l  drugs,  s ince
1) classical neuroleptics differentiate from atypical antipsychotics;
2) combinecl 5llT,- and low D.-antagonism mimics an atypical-like profile;
3) results in acute vs. chronic studies are readily comparable;
4) chronic treatment results suggest a dose-dependent relation between
the compounds and tireir effects.
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To further validate the paradigm of sNr neuronal activity for atypicality
studies in awake animals appear warranted. Moreover, studies are needed with
e,g. additional classical (pimozide) and atypical antipsychotics (ziprasidone, zo-
tepine), atypical drugs using other mechanisms (substituted benzamides), drugs
with EPS but without antipsychotic action, non-dopaminergic putative antipsy-
chotics and with noradrenergic, histaminergic, cholinergic and serotonergic
agents. Finar\, studies in experimental models for schizophrenia, such as the
phencyclidine model, may lend promise in the improvement of our insight into
the role of the SNr in the mechanism of action of antipsychotic clrugs.
Fttnctionol implications SNr ntypicnl antipsrlclntics and Tourette's yndrome.
Is it then possible to correlate the results of our SNr-recordings to the mecha-
nisms of action of the atypical antipsychotics and to the culrent concepts of
basal ganglia functioning?
Firstly, risperidone shows similarities with clozapine and olanzapine and
contrasts haloperidol. This suggests that the effects seen in the SNr correspond
to the atypical properties of clozapine and not to the clopamine-related anti-
psychotic action or motof-related side effects. Consequently, the observed
effects mav relate to the characteristic properties of atypical antipsychotics.
We found that the atypical antipsychotics induced a decrease of SNr-neuronal
activity. The above outlined neuroanatomical schematic model of cortico-sub-
cortical circuitrv predicts that not dopamine receptol blockacle, but doparnine
receptol stimulation incluces a decrease in the firing rate of the SNR-neurons
(Albin et al., 1989; Delong 1990). ln other words, the atypical antipsychotics
produced effects that are compatible with dopamine agonistic activity, within
the cortico-subcortical circuitry model. A cautious interpretation of these fin-
dings would thus be that the dopaminergiclike activity of the atypical anti-
psychotics, found in the SNr, reflects waVS to counteract EPS. It may also indi-
cate a means to alleviate symptoms of motivational disturbance, anhedonia,
and cognitive impairment, conditions generally associated with the hypodo-
paminergic state of hypofrontality in schizophrenia (Weinberger, 1987).
In our sNr-studies doparnine D2 receptor blockade by haloperidol and
raclopride did not change or, in a certain dose range, slightly increased sNr
activity. This latter response is in accordance with the cortico-subcortical circui-
trv model that predicts that dopamine receptor blockade corresponds with an
increased inhibitory action of the basal ganglia output neurons. Previous expe-
rimental studies with dopamine agonists have yielded variable effects, with
both increased and decreased activity (Waszczak et a1., 7984;Walters et al.,
1987). Moreover, the clinical implications of an inhibitory effect on the SNr-
neurons are still far from elucidated. For example, Bejjani et a1. (1999) published
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a case report on electrical stimulation of the SNr in a patient with Parkinson
Disease. The deep brain stimulation, most probably resulting in a functional
inhibit ion of GABAergic neurons, induced clinical features of an acute depres-
sion, but did not affect her motor symptoms. In another case report, cerebral
vascular insult affecting the SNr caused hallucinations and desorientation
(McKee et a1., 1990). Therefore, one must be cautious to interpret the present
data too rigidly in view of a simplif ied model of the basal ganglia functioning
(for a critical review on basal ganglia functioning see Chesselet and Delfs, 1996;
also Parent and Cicchetti, 1998).
In conclusion, at present it is impossible to be conclusive regarding a
potential association between the SNR activity and the mechanisms underlying
atvpical antipsychotic efficacy, although the present findings present an attrac-
t i ve  heu r i s t i c  hypo thes i s .
To draw up an arralogy between the effects of risperidone on the SNr-activity
and risperidone's clinical effect in Tourette's synclrome may be equally complex.
lncreased activity of the SNr is widely proposed to represent part of the mecha-
nism underlying hypokinetic disorclers such as Parkinson's disease (see above).
Conversely, hyperkinetic disorders such as Huntington's Chorea or possibly
even Tourette's syndrome are linkecl to a hypertrctivity of thalamocortical cir-
cuitrv and hence with a decreased activity of the SNr. In this paradigm, the inhi-
bit ion of SNr activity induced by risperidone would predict a clinical worsening
of tic-syrnptoms, which is obviously not the case (cf. below). Interestingly, wor-
sening of ttcs was found after a low dose of clozapine in a small gloup of hyper-
kinetic patients, but no effects were seen in the higher dosages of clozapine
(Caine eI al.,7979). However, the reports on clozapine are of limited number.
There is an apparent paradox between hyperkinetic disorders, the irrhibi-
t ion of the SNr activity by atypical antipsychotics and the beneficial effects of
risperidone in Tourette's synclrome. Furthermore, these clata are at variance
with neurosurgical treatments of Tourette's syndrome, which presumably exert
their action via severing thalamo-cortical and cortico-thalarnic projections (see
Vanclewalle et al., 1999). An explanation for this discrepancy may be found in
the temporal aspect of the medical treatment, i.e. there is a delayecl onset of ris-
peridone's effect on tics of one to two weeks. However, the pathological chan-
ges in Tourette's syndrome arc still unknown arrcl the effects of chronic risperi-
done treatment on the SNr neuronal activitv have not been studiecl vet.
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Tlrc tlrcrapteutic pott:ntial of risperitlorrt' in tlt' treatnrcrtt of Tburettc's syndrotrre
The second part of this thesis aims at identifying the role of risperidone in the
treatment of Tourette's syndrome. Rationale for these studies is the rrotion thart
dopamine antagonists are the mainstay of pharmtrcothertrpy for tic disorclers
but that their use is restricted by their unwanted side effects. Therefore, stucly-
ing tl-re poterrtials of risperidone may provide' new therapy oprtions.
The first step r,vas to assess risperidone's efficacy -if anv- on tics. Next was
then to dete'r"mine lvhether its side effect profile is advantageous to that of the
classical ccrrnpouncls. In chapter 5 risperic'loue is shclwn to tre effective for reclu-
cing tic syrrptoms in a small open-label 4-week study in eleven patients. The
drus was well tolerated with sedation as the most frequently occurring adver-
se reaction. Similar positir,'e results were reportecl shortly after our study by
Lonrbroso ct al., (1995) and by Bruun and Budrnan (7996), who both published
an ofren stucly in childrer-r ar-rd adolescents with tic-disorders. Robertson and
coworkers did fincl a substantial rrumber Qa%) of non-responders, next to a
58% of responders ir-r their group of 24 patients in a case-findinl; stucly (1996).
Notably, these authors alsc'l reported a worsening oi tics in 3 % of tl-reir ptrtient
cohort. The positive findings in these preliminary studies warranted a double-
blincl con'rparative tritr l for risperidone.
ln chapter 6 risperidone is compared with pimozitle in a multicentre, double-
blind parallel group stuclv with a 12-week duratiorr. Pimozide lvas cltosen for
cornparison since it has been the first choice drug for tic-suppression, superior
to halopericlol both in efficacy and tolerability. There was significant improve-
ment of the tics in respect to the Tor-rrette Syrnpton'r Severity Scale (TSSS) for both
groups. Forty-one of the 50 patients completed the study. At the completion to
the stuc-lv 549/, patierrts in the- rispericlone group anc-l 38% patients in the pirno-
zide group had only very rnilcl or no symlrtoms on the global severity ratirrg of
the TSSS. Statistical analysis demonstratecl that both treatn-rent strategies \^1ere
equally effective in terms of tic-su1-rpression. The severity of EPS was low in both
groups, with a lower incidence of people reporting akathisia for rispericlone.
We further studied whether risperidone would be bette-r than pimozide in
reclucing severity of obsessive-cornpulsive symptoms. Although OCB irnpro-
vecl in both treatment groups, symptom reduction, as measured on the Yale-
Brown Obsessive-Compulsive Scale (Y-BOCS), achievecl statistical significarrce
only in the risperidone group. It can be concluded that risperidone' is as effica-
cious as pirnozide in tic suppression and that risperidone is well tolerater-l in
prartients with Tourette's svndrome. Because of this rnore favorable efficacv- and




However, results frorn clinical trials in Tourette's syndrome do not easily
translate into guidelines for daily practice since they are often hampered by
short durations, selective entry-criteria, exclusion of co-morbiditv restriction of
other psychotropic drugs and/or placebo-responses. From this perspective,
longer treatment studies are indicated to cletermine tl-re role of risperidone in TS
treatment. Chapter 7 describes the treatment of Tourette patients with risperi-
clone ancl/or sulpiric' le in a retrosp'rectivc. survev over a three-year period. The
rnain objective of this study was to describe the acceptabil ity ancl dosing requi-
rements of these two atypical antipsychotics over the long term. Sulpiricle was
includeci because of its wide spread use as a first l ine clrug ir.r a nurnber of
European ancl South Africarn courrtries.
The results of this narturalistic study show that long-term treatment with
rispericlone arrd sulpiride leads to discontinuation in approximately half of the
patients within 12 rnonths. Adverse events (such as seclation, clepression and
w,eight gain) and planned clrug-n ithdrawals were the main reasons for discon-
tinuation. EPS were reported irr a substantial number of p.rtients in both
groups. However, patients who continued risperidone or sulpiricle did not clif-
fer from patients free of rnedication, with respect to EPS arrd subjective feelirrgs
of well being. Moreover, this 3-year survey of 36 patients did not reveal a sin-
gle ct.rse of ttrrdive clyskinesia. The naturalistic setting yielcled a r,vide variety of
co-meclication and co-morbiclity, emphasizing the occurrence of possible drug-
drug irrteractions. Limitations of this study include its retrospective nature and
the use of both drugs in a small number of patients. Furthermore the study was
biasecl tor.vards patierrts, r.r,lro successfully cornpletecl plar-ured rlrug-withdra-
wals. Thus, for a selected portion of Tourette's synclrome patients, both risperi-
c' lone anc'l sulpiride were acceptable drugs for t ic suppression, in a mean dosa-
ge of 2.67 ng/ day and 493 mg/c-tay respectively. It can be concluded that, when
rnedication is rreederl in Tcrurette's syrrrlrome, atypical arrtipsychotics, such as
risperidone or sulpiride, should be tried first, before considering for example a
classictrl neuroleptic.
Mecltortism of nctiort o.f risTtt'ritlonc irr Tourctte's srlndronta
The present f indings raise the question how ertvpical antipsychotics can proclu-
ce tic-strppression. The doses of rispericlone used in this study (0.5-6 nrg/clav)
are expectecl to yield botl'r a high 5-H-t2n-receptor occupancy and a rnoderate
up to high Dr-recePtor occupancy. Hence it is feasible that the dopanrine D'-
receptor blockacle accounts fbr the observecl efficacy of rispericlone in tic-sup-
pression. Of note, motor side effects were not completely absent in this stuclV
pointirrg to rr certarin clegree of c{oparnine blc-rckacle in the nigrostriatal system.
On the othtr hand, the fewer EI'S-like adverse events, l.e. less akathisia, in the
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risperidone group lends support to the mesolimbic selectivity for risperidone.
In this respect, the high affinity for S-HT2-receptors relative to D2-receptors ntav
have been contributory to risperidone's favorable EI)S profile. Moreove4, one
should realize that the. 5 HT'A antagonistic properties of arn antipsychotic do not
necessarily irnplicate an overall anti-serotonergic effect. In fact, in experimental
studies risperidone has been shown to indirectly enhance serotonergic activity
(Hertel et al., 7996). Therefore, in acidition to the S-HT" receptor blockade, an
increasecl output of 5-I{T in the cortex acting upon other postsynaptic 5-HT-
receptors n-ray have been supportive for the drug's effects on the obsessive-com-
puisive syrnptoms in this study. Tl-ris notiorr is strengthened by other studies that
have suggested a beneficial role for 5HT1/D' antaplonists such as risperidone and
olanzapine (Stein et a1.,1997; Koran et al., 2000; McDougle et a1., 2000) in the tre-
atment of concurrent OCD ancl tic disorders. Finally, the alpha-1 and alpha-2
adrenoceptor blockade bv risperidone may also have contributecl to its efficacv in
Tourette's syndrome, considering e.g. clonidine's efficacy in Tourette's syndrome.
From a clinical and a research point of view, dosage requirements are of
importance. The mecl-ranism of tic-suppression of antipsychotics in Tourette's
syndrome is probably related to their blockade of striatal dopamine rec€.ptors.
It is generally accepted that extensive blockade (i.e. > 80%) of striatal dopami-
ne-D2 receptors by neuroleptics causes EPS and hyperprolactinaemia. In PET-
studies with schizophrenic patients risperidone at 3 mg/clay corresponds with
70-80'l' D2 receptor occupancy, vvhich is sufficient to induce an antips)ichotic
effect but insufficient to induce EPS (cf. Farde et al., 1992; Kapur et al., 7999).
Similar PET-stuclies in Tourette's syndrome may evaluate the D, receptor occu-
pancy needed for effective tic suppression. This may learn that doses that are
prescribed nowadays in clinical practice may be relatively high. Irr arddition,
such studies rnay answer the question whetl'rer Tourette patients have a lor,r,er
threshold for EPS and/or other side effects in comparison to schizophrenic
patients.
Finally, a comparatively larger therapeutic index for the new atypical
drugs, j.e. a clear separation between the efficacious tic suppressive close and
the EPS inducing dose, would suggests that the atypical mode of action of these
new clru6;s is also applicable to the mechanism of t ic suppression. This would
be circumstantial evidence for the predominance of the mesolimbic system in
the pathology of Tourette's syndrome (see introduction) or it would support the
hypothesis that atypical antipsychotics call upon adclitional non-dopaminergic
receptors for their beneficial effects in Tourette's syndrome.
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Treating tics with atypical antipsr1chotics.
Neuroleptic-treatment for Tourette's syndrome carries several risks and limita-
tions and the new atypical antipsychotics may offer the clinician new thera-
peutic tools. To date, risperidone's efficacy on tics is well established; other
drugs are in the phase of clinical testing.
Several preliminary studies suggested efficacy for olanzapine in tic-suppres-
sion (Benji Semerci, 2000, Karam-Hage and Chaziuddin, 2000). Recently olanza-
pine was found effective in tic suppression in an open study with 14 patients with
Tourette's syndrome, with sedation and weight gain as the major side effects
(Stamenkovic et al., 2000). Another atypical antipsychotic, ziprasidone was effec-
tive and well tolerated in a group of 28 children and adolescents with Tourette's
syndrome in a double-blind placebo controlled study (Sallee et al., 2000). Transient
somnolence was the most commonly reported side effect; akathisia was observed
in one patient, no other Ef'S were detected. Lack of weight gain and only transient
prolactin elevation were encouraging findings. Ziprasidone has sHTz^/ D2 anta-
gonistic properties with additional 5HT1a receptor agonistic properties and it is a
reuptake inhibitor for serotonin en noradrenaline. This pharmacological profile
may be advantageous in the complex symptomatology of Tourette's syndrome.
Another intriguing probe to be tested will be quetiapine, which has a very low
dopamine D, affinity closely resembling clozapine. Clearly, further controlled and
naturalistic studies of atypical antipsychotics are indicated.
If the atypical agents wil l appear to be equally effective in the treatment of
tic-disorders, side effect profiles will become increasingly important. With res-
pect to EPS, both acute and tardive, low doses of risperidone have an advanta-
geous profile over classical neuroleptics. However, of the atypical antipsycho-
tics risperidone has the highest affinity for dopamine receptors. And in
Tourette's syndrome risperidone is clearly not completely devoid of motor side
effects. Moreover, of all the new atypical antipsychotics, risperidone is most
potent in terms of prolactin elevation. In this respect it has no clear advantage
over sulpiride. Thus, in case of prolactin related sexual or endocrine side effects
with either risperidone or sulpiride, a trial with e.g. olanzapine may offer an
alternative treatment option. Albeit that sedation is reported in all the Tourette
studies, risperidone is probably one of the least sedative of the new drugs.
Weight gain, a serious problem with both classical and new antipsychotics
including risperidone, causes large somatic and psychological burden. In a
recent meta-analysis in schizophrenic patients risperidone induced relatively
little weight gain (Allison et al .1999). Whether this sustains also in Tourette's
syndrome needs further study. The threshold for epileptic seizures is lowered
by most classical and atypical antipsychotics, for risperidone the risk of seizu-
res is relatively low (Kasper et al.,1999).In addition, based on its lack of anti-
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cholinergic activity risperidclne nay also be preferable n,ith respect to coguiti-
ve functionirrg. This rnav be especialJy significant, since ptrtients with Tourette's
syndrome ;rre exttemely aware of both their surrounding stimuli and tlreir own
internal cognitive processes.
To sumrnarize, in Part II the therapeutic poterrtial of rispericlone in the treat-
n'rent of Tourette's syndrome was assessecl. First, tl-re efiicacy of risperidone as
a tic-suppressive agent was sl ' lown in an opren rlose-findirrg tritr l. Next, risperi-
done was demonstrated as efficacious as pimozide in a double-blincl study.
Risperidone was well tolerated arrd induced few EPS, with reportediy less rrka-
thisia than primozide. In aclclit ion, it wars suggested that risperidone has benefi-
cial effects on obsessive-compulsive svmptoms. Finally, in a retrospective sur-
vey on rispericlone we founc{ that, after orle year of treatment, a large nuntber
of patients had cliscontinued risperidone, due to general sicle effects or planrred
drug-withclrawal. After one vear, circa one-third of the patierlts was sti l l  using
risperidone saie anc{ eifectively in a dose less than 3 mg/day. The clinical irnpli-
cation that is supported bv this thesis is that risperidone may be a first-l ine
drug in the treartment of Tourette's sytrdrome.
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